

Michael A Beazely

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6569417/michael-a-beazely-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

1,043
citations

17
h-index

32
g-index

47
ext. papers

1,184
ext. citations

4.2
avg, IF

3.94
L-index

#	Paper	IF	Citations
45	Frequently asked questions about naloxone: Part 3.. <i>Canadian Pharmacists Journal</i> , 2022 , 155, 9-11	1.3	0
44	Assessing the impact of a cannabis course on pharmacy studentsUnderstanding, beliefs and preparedness regarding medical and recreational cannabis.. <i>Canadian Pharmacists Journal</i> , 2022 , 155, 50-59	1.3	
43	Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.. <i>Drug Safety</i> , 2022 , 45, 287	5.1	1
42	Frequently asked questions about naloxone: Part 2. <i>Canadian Pharmacists Journal</i> , 2021 , 154, 385-387	1.3	0
41	Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another. <i>Pharmacy (Basel, Switzerland)</i> , 2021 , 9,	2	2
40	The role of pharmacists in opioid stewardship: A scoping review. <i>Research in Social and Administrative Pharmacy</i> , 2021 ,	2.9	3
39	The role of pharmacists in opioid stewardship: Protocol. <i>Research in Social and Administrative Pharmacy</i> , 2021 , 17, 993-996	2.9	1
38	Pseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
37	What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review. <i>Pharmacy (Basel, Switzerland)</i> , 2021 , 9,	2	9
36	Frequently asked questions about naloxone: Part 1. <i>Canadian Pharmacists Journal</i> , 2021 , 154, 301-304	1.3	0
35	Chronic early-life social isolation affects NMDA and TrkB receptor expression in a sex-specific manner. <i>Neuroscience Letters</i> , 2021 , 760, 136016	3.3	2
34	The status of naloxone in community pharmacies across Canada. <i>Canadian Pharmacists Journal</i> , 2020 , 153, 352-356	1.3	3
33	Canadian national consensus guidelines for naloxone prescribing by pharmacists. <i>Canadian Pharmacists Journal</i> , 2020 , 153, 347-351	1.3	3
32	The effects of heat and freeze-thaw cycling on naloxone stability. <i>Harm Reduction Journal</i> , 2019 , 16, 17	4.6	2
31	Amyloid- β Inhibits PDGFR α Receptor Activation and Prevents PDGF-BB-Induced Neuroprotection. <i>Current Alzheimer Research</i> , 2018 , 15, 618-627	3	5
30	Fitting naloxone into community pharmacy practice. <i>Canadian Pharmacists Journal</i> , 2016 , 149, 329-331	1.3	1
29	Data on acylglycerophosphate acyltransferase 4 (AGPAT4) during murine embryogenesis and in embryo-derived cultured primary neurons and glia. <i>Data in Brief</i> , 2016 , 6, 28-32	1.2	6

28	Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease. <i>Chemical Biology and Drug Design</i> , 2016 , 88, 710-723	2.9	6
27	Tricyclic phenothiazine and phenoselenazine derivatives as potential multi-targeting agents to treat Alzheimer's disease. <i>MedChemComm</i> , 2015 , 6, 1930-1941	5	27
26	Fluoxetine-induced transactivation of the platelet-derived growth factor type β receptor reveals a novel heterologous desensitization process. <i>Molecular and Cellular Neurosciences</i> , 2015 , 65, 45-51	4.8	4
25	Transactivation of Receptor Tyrosine Kinases by Dopamine Receptors. <i>Neuromethods</i> , 2015 , 211-227	0.4	
24	Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014 , 10, 1637-47	6	36
23	5-HT ₇ receptor activation promotes an increase in TrkB receptor expression and phosphorylation. <i>Frontiers in Behavioral Neuroscience</i> , 2014 , 8, 391	3.5	15
22	Acute 5-HT ₇ receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. <i>Molecular Brain</i> , 2013 , 6, 24	4.5	33
21	5-HT _{1A} receptors transactivate the platelet-derived growth factor receptor type beta in neuronal cells. <i>Cellular Signalling</i> , 2013 , 25, 133-43	4.9	16
20	5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGF β receptor dependent. <i>Journal of Neurochemistry</i> , 2013 , 125, 26-36	6	22
19	Reactive oxygen species are required for 5-HT-induced transactivation of neuronal platelet-derived growth factor and TrkB receptors, but not for ERK1/2 activation. <i>PLoS ONE</i> , 2013 , 8, e77027	3.7	20
18	Serotonin transactivation of PDGF β receptors results in a heterologous desensitization to subsequent transactivation stimuli. <i>FASEB Journal</i> , 2013 , 27, 882.7	0.9	
17	Activation of 5-HT ₇ receptors increases neuronal platelet-derived growth factor β receptor expression. <i>Neuroscience Letters</i> , 2012 , 511, 65-9	3.3	16
16	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 4707-12	2.9	41
15	Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. <i>Journal of Biological Chemistry</i> , 2010 , 285, 21615-24	5.4	43
14	Postsynaptic clustering and activation of Pyk2 by PSD-95. <i>Journal of Neuroscience</i> , 2010 , 30, 449-63	6.6	56
13	Platelet-derived growth factor selectively inhibits NR2B-containing N-methyl-D-aspartate receptors in CA1 hippocampal neurons. <i>Journal of Biological Chemistry</i> , 2009 , 284, 8054-63	5.4	34
12	Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission. <i>Hippocampus</i> , 2009 , 19, 779-89	3.5	32
11	Abelson tyrosine kinase links PDGF β receptor activation to cytoskeletal regulation of NMDA receptors in CA1 hippocampal neurons. <i>Molecular Brain</i> , 2008 , 1, 20	4.5	10

10	Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. <i>Science</i> , 2008 , 322, 1555-9	33.3	265
9	G protein-coupled receptors control NMDARs and metaplasticity in the hippocampus. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007 , 1768, 941-51	3.8	58
8	Regulatory properties of adenylate cyclases type 5 and 6: A progress report. <i>European Journal of Pharmacology</i> , 2006 , 535, 1-12	5.3	64
7	D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent. <i>Journal of Neurochemistry</i> , 2006 , 98, 1657-63	6	48
6	Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6. <i>Cellular Signalling</i> , 2005 , 17, 647-53	4.9	14
5	Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation. <i>Biochemical Pharmacology</i> , 2005 , 70, 113-20	6	15
4	Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. <i>Molecular Pharmacology</i> , 2005 , 67, 250-9	4.3	39
3	Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line. <i>Journal of Neurochemistry</i> , 2004 , 88, 1497-508	6	11
2	Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells. <i>Journal of Neurochemistry</i> , 2002 , 82, 1087-96	6	18
1	Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds. <i>European Journal of Medicinal Chemistry</i> , 2000 , 35, 967-77	6.8	59